Clinical Trial: Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1)

U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06867718) titled 'Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1)' on Feb. 14.

Brief Summary: This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.

Study Start Date: Jan. 24

Study Type: INTERVENTIONAL ...